The LODH Immunology Fund is a Swiss open-ended mutual fund managed by Lombard Odier Darier Hentsch & Cie, a Swiss private bank. Approximately 20% of the assets of the fund are invested in privately held biotech companies.
| Company | Date | Round | Size | Participants |
| NovImmune | 5/09 | Series D | $54.8M | 7 |
| NovImmune | 5/00 | Series A | $14M | 2 |
